Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1

doi:10.3877/cma.j.issn.1674-6902.2021.05.003

Abstract

Abstract:

Objective

To investigate the effect and mechanism of microRNA-515-5p (miR-515-5p) on the cisplatin sensitivity of non-small cell lung cancer (NSCLC).

Methods

The expression of miR-515-5p in BEAS-2B, A549 and A549/DDP cells was detected by real-time fluorescent quantitative PCR (RT-qPCR). A549/DDP cells were divided into NC group, miR-515-5p group, si-RING1 group and miR-515-5p inh+ si-RING1 group. CCK-8 assay was used to assess the proliferation of A549/DDP cells. WB was performed to measure the expression of RING1 and apoptosis related proteins. Dual luciferase reporter gene system was used to verify the targeting relationship between miR-515-5p and RING1.

Results

The expression of miR-515-5p in BEAS-2B, A549 and A549/DDP cells were (1.00±0.03), (0.61±0.03), (0.31±0.04), respectively. A549/DDP cells were transfected with miR-515-5p mimics, the OD₄₅₀ values of cells in NC group and miR-515-5p group at 24, 48, 72 and 96 h were (0.61±0.02), (0.52±0.02), (0.84±0.02), (0.68±0.04), (1.03±0.03), (0.79±0.04), (1.08±0.03), (0.86±0.04), respectively. The differences of those items were all statistically significant (all P<0.05). The expression of cleaved caspase-3, cleaved PARP and Bax in miR-515-5p group were significantly higher than those in NC group, and the expression of Bcl-2 were significantly lower than those in NC group. A549/DDP cells were transfected with si-RING1 and miR-515-5p inhibitor, the OD₄₅₀ values of cells in NC group, si-RING1 group and miR-515-5p inh+ si-RING1 group at 24, 48, 72 and 96 h were (0.63±0.02), (0.49±0.04), (0.58±0.03), (0.83±0.03), (0.62±0.05), (0.80±0.02), (1.05±0.04), (0.76±0.03), (1.02±0.04), (1.15±0.05), (0.86±0.03), (1.12±0.06), respectively. The differences of those items were all statistically significant (all P<0.05). The expression of cleaved caspase-3, cleaved PARP and Bax in si-RING1 group were significantly higher than those in NC group and miR-515-5p inh+ siRING1 group, and the expression of Bcl-2 were significantly lower than those in NC group and miR-515-5p inh+ siRING1 group.

Conclusion

miR-515-5p enhanced the cisplatin sensitivity of A549/DDP cells through targeting downregulate the expression of RING1.

Key words: MicroRNA-515-5p, Ring finger protein 1, Non-small cell lung cancer, Cisplatin sensitivity

Rui Xu, Yong Qian, Haiyan Zhang. Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 559-563.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2021.05.003

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2021/V14/I05/559

Figures/Tables 5

References 31

1	Yang B, Zheng D, Zeng U, et al. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients[J]. J BUON, 2018, 23(4): 1077-1081.
2	Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.
3	肖丹，杜琴，贺斌峰，等. YAP调控肺癌A549/DDP细胞顺铂耐药性的机制分析[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(6): 697-701.
4	Rao C, Miao X, Zhao G, et al. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9[J]. Biomed Pharmacoth, 2019, 114: 108662.
5	Zhou H, Li J, Zhang Z, et al. RING1 and YY1 binding protein suppresses breast cancer growth and metastasis[J]. Int J Oncol, 2016, 49(6): 2442-2452.
6	Zhou Y, Wan C, Liu Y, et al. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer[J]. Pathol Oncol Res, 2014, 20(3): 549-556.
7	Shen J, Li P, Shao X, et al. The E3 ligase RING1 targets p53 for degradation and promotes cancer cell proliferation and survival[J]. Cancer Res, 2018, 78(2): 359-371.
8	Xiong Y, Hu B, Wei L, et al. Upregulated expression of polycomb protein Ring1 contributes to poor prognosis and accelerated proliferation in human hepatocellular carcinoma[J]. Tumour Biol, 2015, 36(12): 9579-9588.
9	Hu B, Zhang H, Wang Z, et al. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4[J]. Cancer Biol Ther, 2017, 18(12): 974-983.
10	Xu G, Zhang Z, Zhang L, et al. miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2[J]. Molecul Cellul Biochem, 2018, 443(1-2): 151-157.
11	Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method[J]. Methods, 2001, 25(4): 402-408.
12	Chen K, Abuduwufuer A, Zhang H, et al. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(16): 6935-6943.
13	Guo J, Jin D, Wu Y, et al. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells[J]. EBioMedicine, 2018, 35: 204-221.
14	Li J H, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data[J]. Nucleic Acids Res, 2014, 42(Database issue): D92-D97.
15	Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer[J]. Expert Opin Biol Ther, 2012, 12(9): 1221-1239.
16	Wang S, Li MY, Liu Y, et al. The role of microRNA in cisplatin resistance or sensitivity[J]. Expert Opin Ther Targets, 2020, 24(9): 885-897.
17	Lu X, Liu R, Wang M, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer[J]. Oncogene, 2019, 39(1): 234-247.
18	Rong F, Liu L, Zou C, et al. MALAT1 promotes cell tumorigenicity through regulating miR-515-5p/EEF2 axis in non-small cell lung cancer[J]. Cancer Manag Res, 2020, 12: 7691-7701.
19	Liu J, Eckert MA, Harada BT, et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer[J]. Nature Cell Biol, 2018, 20(9): 1074-1083.
20	Van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features[J]. Eur Urol, 2007, 52(2): 455-463.
21	Yuan XW, Yan TQ, Tong H. Effect of miR-515-5p on proliferation and drug sensitivity of retinoblastoma cells[J]. Cancer Manag Res, 2020, 12: 12087-12098.
22	Zhong Y, Wang D, Ding Y, et al. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p[J]. Biotechnol Lett, 2021, 43(2): 339-351.
23	Han Y, Li F, Xie J, et al. PVT1 mediates cell proliferation, apoptosis and radioresistance in nasopharyngeal carcinoma through regulating miR-515-5p/PIK3CA axis[J]. Cancer Manag Res, 2020, 12: 10077-10090.
24	Qiao K, Ning S, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 418.
25	Wang D, Liu K, Chen E. LINC00511 promotes proliferation and invasion by sponging miR-515-5p in gastric cancer[J]. Cell Molecul Biol Lett, 2020, 25: 4.
26	Zhang Y, Shi Z, Li Z, et al. Circ_0057553/miR-515-5p regulates prostate cancer cell proliferation, apoptosis, migration, invasion and aerobic glycolysis by targeting YES1[J]. Onco Targets Ther, 2020, 13: 11289-11299.
27	Zhang X, Zhou J, Xue D, et al. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer[J]. Int J Biol Macromol, 2019, 129: 227-232.
28	Ni JS, Zheng H, Ou YL, et al. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway[J]. Surg Oncol, 2020, 34: 113-120.
29	Guo F, Li S, Guo C, et al. Circular RNA circMAGI3 accelerates the glycolysis of non-small cell lung cancer through miR-515-5p/HDGF[J]. Am J Transl Res, 2020, 12(7): 3953-3963.
30	Wang Y, Zhang Q. Long noncoding RNA MALAT1 knockdown inhibits proliferation, migration, and invasion and promotes apoptosis in non-small-cell lung cancer cells through regulating miR-515-3p/TRIM65 axis[J]. Cancer Biother Radiopharm, 2020, doi: 10.1089/cbr.2020.3730.
31	Li J, Tang Z, Wang H, et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p[J]. Biomed Pharmacother, 2018, 97: 182-1188.

分　组	24 h	48 h	72 h	96 h
NC组	0.61±0.02	0.84±0.02	1.03±0.03	1.08±0.03
miR-515-5p组	0.52±0.02^a	0.68±0.04^a	0.79±0.04^a	0.86±0.04^a

分　组	24 h	48 h	72 h	96 h
NC组	0.61±0.02	0.84±0.02	1.03±0.03	1.08±0.03
miR-515-5p组	0.52±0.02^a	0.68±0.04^a	0.79±0.04^a	0.86±0.04^a

分　组	24 h	48 h	72 h	96 h
NC组	0.63±0.02	0.83±0.03	1.05±0.04	1.15±0.05
si-SING1组	0.49±0.04^a	0.62±0.05^a	0.76±0.03^a	0.86±0.03^a
miR-515-5p inh　+si-RING1组	0.58±0.03^b	0.80±0.02^b	1.02±0.04^b	1.12±0.06^b

分　组	24 h	48 h	72 h	96 h
NC组	0.63±0.02	0.83±0.03	1.05±0.04	1.15±0.05
si-SING1组	0.49±0.04^a	0.62±0.05^a	0.76±0.03^a	0.86±0.03^a
miR-515-5p inh　+si-RING1组	0.58±0.03^b	0.80±0.02^b	1.02±0.04^b	1.12±0.06^b

[1]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[2]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[3]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[4]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[5]	Xiaoqin Weng, Jiayang Qin, Yang Zhang, Jin Cui, Hong Shen. Effect of HIF-1α/VEGF-VEGFR2/Nrp-1 on Treg proliferation in NSCLC patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 717-722.
[6]	Zhiguo Yu, Bo Gong, Weihua Lu, Minfang Li. Silencing HIF-1α regulates MAPK/ERK pathway and inhibits metastasis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 573-578.
[7]	Xuan Wang, Lichun Cui, Shengqiang Dang. Effect of apatinib and Erica on the expression of immune cell surface molecules in patients with NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 554-558.
[8]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[9]	Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.
[10]	Jingxiu Niu, Lihong Zhang, Hui Wang. Clinical study on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer by grey screening method [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 774-778.
[11]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[12]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[13]	Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.
[14]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.
[15]	Gang Jin, Keying Yao, Xingwei Shen, Long Ma, Zijiang Zhu. Efficacy of anti-PD-1/PD-L1 inhibitors versus docetaxel in the treatment of non-small cell lung cancer: a systematic review and meta-analysis [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2021, 08(04): 239-246.

Please choose a citation manager

Content to export